PKC 412 small‐molecule tyrosine kinase inhibitor

Abstract

These data highlight that PKC412 may be a new compound in target therapy of inoperable pancreatic cancer patients and suggest a potential role for the combined use of broad spectrum kinase inhibitors in the management of these patients.